Ascites in Hepatitis C Liver Transplant Recipients Frequently Occurs in the Absence of Advanced Fibrosis

Department of Surgery, Division of Transplantation, University of California - San Francisco, San Francisco, CA, USA.
American Journal of Transplantation (Impact Factor: 5.68). 03/2008; 8(2):366-76. DOI: 10.1111/j.1600-6143.2007.02046.x
Source: PubMed


Ascites after liver transplantation is uncommon (3-7%) but causes morbidity and mortality. Although hepatitis C (HCV), pretransplant ascites, encephalopathy and cold ischemia time have been identified as predictors, neither posttransplant renal function nor the severity of recurrent HCV (inflammatory grade; fibrosis stage) has been systematically assessed. Among 173 HCV transplants (1 January 1998 to 31 December 2002), 18 patients (10%) developed posttransplant ascites. Cox proportional hazards models identified recipient female gender (hazard ratio [HR]= 12.18; p = 0.0001), cold ischemia time (HR = 1.17 per incremental hour; p = 0.021) and posttransplant creatinine (Cr) (HR = 1.56 per incremental 1.0 mg/dL; p = 0.0052) as independent predictors. Ludwig-Batts inflammation grade (HR = 1.32; p = 0.36) and fibrosis stage (HR = 1.63; p = 0.12) were not significant predictors. The 18 recipients had 19 ascites episodes; 12/19 had fibrosis stage 0, 1 or 2 (10/12 with stage 0 or 1). All 12 lacked diagnostic parenchymal or vascular histopathology. Renal function at ascites diagnosis were similar for transplants with fibrosis stage 0, 1 or 2 versus 3 or 4 (1.8 +/- 1.6 vs. 1.6 +/- 0.6 mg/dL; Cr clearance 39.6 +/- 15.6 vs. 39.3 +/- 13.4 mL/min/1.73 m(2)). In conclusion, recipient female gender, cold ischemia time and poor posttransplant renal function were independent predictors of ascites after HCV liver transplantation. Two thirds of ascites episodes, however, occurred without significant fibrosis or histopathology.

7 Reads
  • Gastroentérologie Clinique et Biologique 08/2008; 32(8):721-726. DOI:10.1016/j.gcb.2008.05.007 · 1.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is limited information on the long-term outcome in liver transplant (LT) subjects undergoing partial splenic embolization (PSE) prior to full dose pegylated interferon/ribavirin (peg-IFN/RBV). Retrospective review of eight LT subjects after PSE and antiviral therapy. Baseline platelets and neutrophils were <50 000 cells/mL and <1000 cells/mL in 75% and 50%. Mean splenic infarction volume was 85 +/- 13%. PSE produced major complications in three (37.5%): recurrent sterile netrophilic ascites and renal insufficiency (n = 2), and splenic abscess (n = 1). Full-dose peg-IFN/RBV was started in seven (87.5%), with two early withdrawals (28.6%) despite early virological response (toxicity and infection); both subjects died. Anemia led to RBV dose-adjustment in six (86%), with human recombinant erythropoietin (EPO) use in four (57%). No peg-IFN adjustments or granulocyte-colonies stimulating factor were needed. Two patients reached sustained virological response (SVR) (28.6%). Two non-responders maintained prolonged therapy with biochemical/histological improvement. After a median follow-up of 151 wk, we observed significant improvements in hematological parameters, aspartate aminotransferase, alanine aminotransferase, international normalized ratio, and prothrombin activity. Extensive PSE after LT produced significant morbidity (37.5%). Peg-IFN/RBV was completed in five out of seven (71%), with SVR in two (28.6%). RBV adjustement due to anemia was high despite EPO use. Only patients able to complete or maintain antiviral therapy survived, with long-term significant benefits in hematological parameters and liver function tests.
    Clinical Transplantation 10/2009; 24(3):366-74. DOI:10.1111/j.1399-0012.2009.01081.x · 1.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transjugular intrahepatic portosystemic shunt (TIPS) is a minimally invasive procedure used to relieve the signs and symptoms of portal hypertension in patients with liver disease. The most common indications for placement are refractory ascites and variceal hemorrhage. In properly selected candidates, TIPS can serve as a bridge to liver transplantation. Expertise in the placement of TIPS following transplantation has significantly increased, allowing the procedure to become a viable option for re-transplant candidates with consequences of recurrent portal hypertension due to portal vein thrombosis (PVT), recurrent liver disease, or hepatic vein outflow obstruction (HVOO). However, TIPS in liver transplant recipients is associated with a lower clinical response and higher rate of complications than in patients with native liver disease and is therefore generally reserved for patients with a MELD < 15. The role of TIPS in non-liver transplant recipients has been well studied in large trials and translates well into clinical applicability to OLT candidates. However, the experience in OLT recipients is heterogeneous and restricted to small series. Thus the focus here is to review the current literature and discuss the proper use of TIPS in liver transplant recipients. Liver Transpl , 2013. © 2013 AASLD.
    Liver Transplantation 02/2014; 20(2). DOI:10.1002/lt.23775 · 4.24 Impact Factor
Show more


7 Reads